- Another leading coronavirus vaccine candidate was able to generate immune responses in healthy volunteers, according to results published Monday.
- It’s the first look at human data for AstraZeneca’s vaccine candidate, which was originally developed by University of Oxford scientists.
- The early data, published in The Lancet, showed the results of 543 vaccinated volunteers.
- It’s still not clear what level of immune response is needed to protect people from the virus. Larger trials are now underway to determine if the experimental shot prevents infection or disease.
- Vaccine candidates developed by Pfizer and Moderna also elicited immune responses in early clinical trials published in July. There are more than 150 vaccine programs underway, and more than 20 are now in human testing.
- Visit Business Insider’s homepage for more stories.
The frontrunners in the race for a coronavirus vaccine have all cleared the first hurdle.
In early human testing, vaccine programs led by AstraZeneca, Pfizer, and Moderna were all successful in generating immune responses in healthy volunteers. Researchers described each program as generally safe and tolerable, supporting further testing for each shot.
AstraZeneca became the latest to release early human data, publishing Monday its first clinical results in The Lancet. The vaccine was given to 543 volunteers.
The researchers reported no serious side effects from the vaccine, but 70% of the vaccinated volunteers experienced fatigue and 68% had headaches, higher rates than a control group given a meningitis vaccine.
“There is still much work to be done before we can confirm if our vaccine will help manage the COVID-19 pandemic, but these early results hold promise,” University of Oxford Professor Sara Gilbert said in a statement Monday.
The positive early results still don’t determine if the vaccine works
It’s not clear what level of immune response will protect people from the virus. Large-scale trials, enrolling tens of thousands of people, are now underway to test AstraZeneca’s vaccine in the UK, South Africa, and Brazil. The British drugmaker is aiming to also start a late-stage trial in the US in August.
These final tests will determine if the vaccine can actually prevent infections or disease, comparing vaccinated volunteers against a group receiving a placebo.
Moderna is planning to start its final stage of testing on July 27, and Pfizer executives said they are also hoping to launch its pivotal study this month. Additional vaccine candidates led by Johnson & Johnson and Novavax are aiming to start these large efficacy trials this fall.
All these programs are pursuing an unprecedented timeline in vaccine development. It typically takes multiple year to craft a vaccine, test it in trials, and manufacture the shot at scale. Given the urgency of the pandemic, drugmakers have been closely working with world governments to shorten that process to a matter of months.
AstraZeneca, Pfizer, and Moderna have all said they are hoping to be ready as soon as this fall for potential emergency use of their vaccines. Their vaccines would be greatly limited in quantity, and it’s unclear how much clinical data would be available to support a regulatory decision that soon.
Oxford scientists developed the shot to avoid pre-existing immunity concerns
The shot was developed by University of Oxford scientists. They rigged a chimpanzee version of the common cold virus, called the adenovirus, to carry the spike protein, a critical element of the novel coronavirus. Scientists used a chimp version of the virus to avoid any concerns of pre-existing immunity to the adenovirus.
This issue flared up for another early coronavirus vaccine candidate developed by the Chinese biotech CanSino Biologics. That program used a human adenovirus, and about half of the human volunteers had pre-existing immunity to that virus. This weakened the immune response to the vaccine, according to clinical results published in May.
AstraZeneca joined in on the effort in late-April, and has supercharged its manufacturing and testing strategy. That has included inking a $1.2 billion deal with the US government, supplying up to 400 million doses to Europe at no profit, and reaching agreements with global nonprofits to distribute its shot to low- and middle-income countries.